Oral Cephalexin Dosing for Cellulitis in an 8-Month-Old Infant
For an 8-month-old infant with cellulitis, administer oral cephalexin at 25-50 mg/kg/day divided into 3-4 doses (every 6-8 hours), with a typical dose of 25 mg/kg/dose every 6 hours for a total of 10 days.
Dosing Rationale
The FDA-approved pediatric dosing for cephalexin is 25-50 mg/kg/day in divided doses 1. For skin and soft tissue infections specifically, the standard approach is to divide this total daily dose into 3-4 administrations throughout the day 1.
Practical Dosing Strategy
- Standard dosing: 25 mg/kg/dose every 6 hours (100 mg/kg/day total)
- For more severe infections: Up to 50 mg/kg/dose every 6 hours (200 mg/kg/day total) 1
- Duration: 10 days is the standard treatment course 2
Evidence Supporting This Approach
The IDSA guidelines for MRSA infections recommend oral cephalexin 75-100 mg/kg/day in 3 or 4 doses for methicillin-susceptible Staphylococcus aureus (MSSA) skin infections 3. While these guidelines address pneumonia and MRSA specifically, they provide the framework for first-generation cephalosporin dosing in pediatric infections.
For cellulitis in infants, the most common pathogens are Group A Streptococcus and MSSA. Cephalexin provides excellent coverage for both organisms 1.
Recent Pharmacokinetic Data
A 2025 pharmacokinetic study in infants 7-60 days old demonstrated that 25 mg/kg/dose every 6 hours achieves adequate pharmacodynamic targets (free time above MIC >50% of dosing interval) for Enterobacterales and MSSA 4. For an 8-month-old infant with more mature renal function, this dosing remains appropriate and achieves therapeutic concentrations.
Clinical Considerations
When to Consider Higher Dosing
Higher doses (approaching 50 mg/kg/dose every 6 hours) should be considered if:
- The cellulitis is extensive or rapidly progressive
- There are signs of systemic toxicity (fever, irritability, poor feeding)
- The infant has failed initial lower-dose therapy
- Local MSSA resistance patterns suggest higher MICs
Alternative Dosing Frequencies
While four-times-daily dosing is FDA-approved and optimal, three-times-daily dosing (every 8 hours) may be considered for adherence purposes 5, 6. Recent pediatric studies support 25-45 mg/kg/dose three times daily for MSSA infections, though this is slightly less conservative for an 8-month-old with cellulitis 6, 7.
Important caveat: For an 8-month-old, I recommend maintaining the every-6-hour schedule initially to ensure adequate drug exposure, as infants have different absorption and clearance patterns than older children 4.
Treatment Monitoring
- Expect clinical improvement within 48-72 hours 3
- If no improvement or worsening occurs, consider:
- Inadequate source control (abscess requiring drainage)
- MRSA infection (switch to clindamycin or TMP-SMX if age-appropriate)
- Alternative diagnosis
- Need for parenteral therapy
When Oral Therapy May Not Be Appropriate
Consider parenteral antibiotics if the infant has:
- Signs of systemic inflammatory response (temperature instability, tachycardia, poor perfusion)
- Inability to tolerate oral medications
- Rapidly progressive infection
- Periorbital or facial cellulitis (higher risk of serious complications)
Safety Profile
Cephalexin is well-tolerated in infants. The most common adverse effects are gastrointestinal (diarrhea, nausea), which occur in <5% of patients 8. Serious adverse reactions are rare. Monitor for allergic reactions, particularly if there is a family history of penicillin allergy (though cross-reactivity with cephalosporins is <3% for non-anaphylactic penicillin allergies).
Note: Cephalexin is inactive against MRSA 1. If MRSA is suspected based on local epidemiology, purulent drainage, or treatment failure, switch to clindamycin 10-13 mg/kg/dose every 6-8 hours (maximum 40 mg/kg/day) 9, 2.